Bing Dai

1.6k total citations · 1 hit paper
31 papers, 1.1k citations indexed

About

Bing Dai is a scholar working on Nephrology, Genetics and Molecular Biology. According to data from OpenAlex, Bing Dai has authored 31 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Nephrology, 12 papers in Genetics and 11 papers in Molecular Biology. Recurrent topics in Bing Dai's work include Genetic and Kidney Cyst Diseases (11 papers), Renal Diseases and Glomerulopathies (6 papers) and Genetic Syndromes and Imprinting (4 papers). Bing Dai is often cited by papers focused on Genetic and Kidney Cyst Diseases (11 papers), Renal Diseases and Glomerulopathies (6 papers) and Genetic Syndromes and Imprinting (4 papers). Bing Dai collaborates with scholars based in China, United States and Switzerland. Bing Dai's co-authors include Changlin Mei, Lili Fu, Yawei Liu, Yiyi Ma, Dongping Chen, Rudolf P. Wüthrich, Lin Li, Ming Wu, Xiaohong Hu and Rongrong Bian and has published in prestigious journals such as PLoS ONE, Kidney International and American Journal of Kidney Diseases.

In The Last Decade

Bing Dai

27 papers receiving 1.1k citations

Hit Papers

Treatment of Persistent Gross Hematuria with Tranexamic A... 2017 2026 2020 2023 2017 100 200 300 400 500

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bing Dai China 13 359 302 292 245 213 31 1.1k
Anurag Singh United Kingdom 9 58 0.2× 203 0.7× 428 1.5× 83 0.3× 33 0.2× 18 906
Mutsuyoshi Kazama Japan 20 87 0.2× 339 1.1× 83 0.3× 146 0.6× 98 0.5× 80 1.6k
Thomas Sitter Germany 23 64 0.2× 209 0.7× 659 2.3× 425 1.7× 25 0.1× 76 1.5k
Lysette N. Broekhuizen Netherlands 9 33 0.1× 76 0.3× 149 0.5× 138 0.6× 74 0.3× 16 756
R. Brunkhorst Germany 17 79 0.2× 151 0.5× 317 1.1× 110 0.4× 15 0.1× 35 885
Jacek Zachwieja Poland 15 168 0.5× 272 0.9× 345 1.2× 73 0.3× 9 0.0× 85 870
A. J. Erslev United States 20 115 0.3× 248 0.8× 128 0.4× 67 0.3× 166 0.8× 54 1.4k
Anja Urbschat Germany 17 25 0.1× 202 0.7× 223 0.8× 145 0.6× 19 0.1× 34 808
Eriko Morishita Japan 24 59 0.2× 204 0.7× 73 0.3× 245 1.0× 18 0.1× 166 1.7k

Countries citing papers authored by Bing Dai

Since Specialization
Citations

This map shows the geographic impact of Bing Dai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bing Dai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bing Dai more than expected).

Fields of papers citing papers by Bing Dai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bing Dai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bing Dai. The network helps show where Bing Dai may publish in the future.

Co-authorship network of co-authors of Bing Dai

This figure shows the co-authorship network connecting the top 25 collaborators of Bing Dai. A scholar is included among the top collaborators of Bing Dai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bing Dai. Bing Dai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Chen, Zewei, Shuangcheng Alivia Wu, Wenyu Liu, et al.. (2025). The role of obinutuzumab in rituximab-refractory membranous nephropathy and minimal change disease. Clinical Kidney Journal. 18(3). sfaf039–sfaf039. 2 indexed citations
3.
Xu, Jing, Cheng Xue, Lingling Liu, et al.. (2023). A pilot study of intensive short‐time continuous renal replacement therapy to substitute maintenance hemodialysis during transitional period of COVID‐19. Therapeutic Apheresis and Dialysis. 28(2). 321–328. 1 indexed citations
4.
Chen, Jing, Lingling Liu, Cheng Xue, et al.. (2022). In-center Nocturnal Hemodialysis Reduced the Circulating FGF23, Left Ventricular Hypertrophy, and All-Cause Mortality: A Retrospective Cohort Study. Frontiers in Medicine. 9. 912764–912764. 2 indexed citations
5.
Lyu, Wentao, Xiuting Liu, Lizhi Lu, et al.. (2021). Cecal Microbiota Modulates Fat Deposition in Muscovy Ducks. Frontiers in Veterinary Science. 8. 609348–609348. 27 indexed citations
6.
Liu, Xiuting, Wentao Lyu, Lei Liu, et al.. (2021). Comparison of Digestive Enzyme Activities and Expression of Small Intestinal Transporter Genes in Jinhua and Landrace Pigs. Frontiers in Physiology. 12. 669238–669238. 10 indexed citations
7.
Mei, Shuqin, et al.. (2020). A 64-year-old woman with raccoon eyes following kidney biopsy: a case report. BMC Nephrology. 21(1). 140–140. 2 indexed citations
8.
Ma, Yiyi, Yuqiang Zhang, Chaoyang Ye, et al.. (2019). Catheterization in a patient with end-stage renal disease through persistent left superior vena cava: a rare case report and literature review. BMC Nephrology. 20(1). 202–202. 9 indexed citations
9.
Gao, Xiang, Hua Li, Chaoyang Ye, et al.. (2019). A dialysis patient with isolated persistent left superior vena cava. Kidney International. 95(4). 1000–1000. 1 indexed citations
10.
Chen, Dongping, Yiyi Ma, Xueqi Wang, et al.. (2014). Clinical Characteristics and Disease Predictors of a Large Chinese Cohort of Patients with Autosomal Dominant Polycystic Kidney Disease. PLoS ONE. 9(3). e92232–e92232. 29 indexed citations
11.
Dai, Bing. (2013). Fructus Xanthii Poisoning: A Case Report and Literature Review. Zhongguo quanke yixue. 2 indexed citations
12.
Xue, Cheng, Bing Dai, & Changlin Mei. (2013). Long-Term Treatment with Mammalian Target of Rapamycin Inhibitor Does Not Benefit Patients with Autosomal Dominant Polycystic Kidney Disease: A Meta-Analysis. Nephron Clinical Practice. 124(1-2). 10–16. 14 indexed citations
13.
Liu, Yawei, Wenyuan Guo, Jiayou Zhang, et al.. (2013). Urinary Interleukin 18 for Detection of Acute Kidney Injury: A Meta-analysis. American Journal of Kidney Diseases. 62(6). 1058–1067. 94 indexed citations
14.
Dai, Bing, Yawei Liu, Lili Fu, et al.. (2012). Effect of Theophylline on Prevention of Contrast-Induced Acute Kidney Injury: A Meta-analysis of Randomized Controlled Trials. American Journal of Kidney Diseases. 60(3). 360–370. 43 indexed citations
15.
Li, Yongchuan, Yawei Liu, Lili Fu, Changlin Mei, & Bing Dai. (2012). Efficacy of Short-Term High-Dose Statin in Preventing Contrast-Induced Nephropathy: A Meta-Analysis of Seven Randomized Controlled Trials. PLoS ONE. 7(4). e34450–e34450. 65 indexed citations
16.
Liu, Yawei, et al.. (2011). Rosiglitazone Inhibits Transforming Growth Factor-β1 Mediated Fibrogenesis in ADPKD Cyst-Lining Epithelial Cells. PLoS ONE. 6(12). e28915–e28915. 28 indexed citations
17.
Liu, Yawei, Bing Dai, Lili Fu, Jieshuang Jia, & Changlin Mei. (2010). Rosiglitazone Inhibits Cell Proliferation by Inducing G1 Cell Cycle Arrest and Apoptosis in ADPKD Cyst‐Lining Epithelia Cells. Basic & Clinical Pharmacology & Toxicology. 106(6). 523–530. 20 indexed citations
18.
Dai, Bing, et al.. (2007). Polo‐like kinase 1 regulates RhoA during cytokinesis exit in human cells. Cell Proliferation. 40(4). 550–557. 7 indexed citations
19.
Wang, Wenjing, et al.. (2006). Aberrant expression of SPARC and its impact on proliferation and apoptosis in ADPKD cyst-lining epithelia. Nephrology Dialysis Transplantation. 21(5). 1278–1288. 9 indexed citations
20.
Zhang, Shuzhong, Changlin Mei, Bing Dai, et al.. (2005). Mutation Analysis of Autosomal Dominant Polycystic Kidney Disease Genes in Han Chinese. Nephron Experimental Nephrology. 100(2). e63–e76. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026